组织因子
重组因子VIIa
因子VIIa
因素七
因子X
组织因子途径抑制剂
凝血酶
凝结
血小板
抗凝血酶
医学
凝血酶原酶
药理学
凝血活酶
内科学
肝素
作者
Dougald M. Monroe,Maureane Hoffman,Julie A. Oliver,Harold R. Roberts
标识
DOI:10.1046/j.1365-2141.1997.4463256.x
摘要
High-dose recombinant factor VIIa has been successfully used as therapy for haemophiliacs with inhibitors. The mechanism by which high-dose factor VIIa supports haemostasis is the subject of some controversy. Postulating a mechanism in which activity is dependent on tissue factor at the site of injury explains the localization of activity but not the requirement for high doses. Postulating a mechanism in which factor VIIa acts on available lipid independently of tissue factor explains the requirement for high doses but not the lack of systemic procoagulant activity. We report that factor VIIa bound weakly to activated platelets (Kd approximately 90 nM). This factor VIIa was functionally active and could initiate thrombin generation in the presence of plasma concentrations of prothrombin, factor X, factor V, antithrombin III and tissue factor pathway inhibitor. The activity was not dependent on tissue factor. The concentration of factor VIIa required for detectable thrombin generation agreed well with the lowest concentration of factor VIIa required for efficacy in patients. High-dose factor VIIa may function on the activated platelets that form the initial haemostatic plug in haemophilic patients. These observations are in agreement with clinical trials which have shown that high-dose factor VIIa was haemostatically effective without causing systemic activation of coagulation.
科研通智能强力驱动
Strongly Powered by AbleSci AI